Although there are currently generic products for more than half of the veterinary dewormers in use, anthelmintics with Milbemycin oxime and Praziquantel are still insufficiently represented and promoted. The purpose of this study, which consists of the clinical and coproparasitological evaluation of the efficiency and risks of the generic product Milbenin in canine anthelmintic therapy, falls within this context. The research was carried out on 20 mixed-breed dogs (common breed; 7 males and 13 females), aged between 1-10 years, from a shelter administered by a private company for the protection and adoption of community dogs, from northwestern Romania. The study consisted of routine clinical examinations and the collection of individual faecal samples, followed by copro-parasitological investigations (n=20) using qualitative methods (modified Willis ovoscopic and Baermann larvoscopic) to evaluate the intensity of natural parasitism with Toxocara canis and Dipylidium caninum. Infested dogs were treated with Milbenin, one tablet for 5-25 kg of body weight, according to manufacturer’s instruction. The results obtained revealed a very good therapeutic efficacy of this new generic product, expressed by the clinical recovery and coproparasitological negativity of 18 of the dogs, representing 90% of the sample of treated patients. According to the administered dose, the active substances achieved mean plasma concentrations of 1 (0.5-2.4) mg/kg for Milbemycin oxime and 10.9 (5-23.6) mg/kg for Praziquantel, respectively. Given the high prevalence of canine helminth infestations especially among the shelter dogs, the results of this study are relevant and timely for outlining the prophylactic-curative conduct of endoparasitism with a new generic product based on milbemycin oxime and praziquantel - highly active molecules with a broad antiparasitic spectrum.

Download Full Text - PDF